Last SFr.92.35 CHF
Change Today -1.20 / -1.28%
Volume 4.1M
NOVN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
Frankfurt
As of 11:43 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Enrico Vanni Ph.D.

Vice Chairman, Chairman of Compensation Committee, Member of Audit & Compliance Committee and Member of Research & Development Committee, Novartis AG
AgeTotal Calculated CompensationThis person is connected to 36 board members in 3 different organizations across 3 different industries.

See Board Relationships
63SFr.751,032

Background*

Dr. Enrico Vanni, Ph.D., serves as an Independent Consultant of Eclosion (private equity for biotechs), Denzler&Partners (management resources) and Mbcp (private banking). Dr. Vanni has more than 30 years of healthcare management experience. He served as head of the European pharmaceutical practice for McKinsey&Company. He started his career in 1977 with IBM in San Jose, California, and joined McKinsey & Company in Zurich, Switzerland. He managed the Geneva Office from ...

Read Full Background

Corporate Headquarters*

Lichtstrasse 35
Basel, Basel-Stadt 4056

Switzerland

Phone: 41 61 324 11 11
Fax: --

Board Members Memberships*

2010-Present
Director, Member of Audit Committee and Member of Nominating/Corporate Governance Committee
2011-Present
Vice Chairman, Chairman of Compensation Committee, Member of Audit & Compliance Committee and Member of Research & Development Committee
2013-Present
Non-Executive Director

Education*

MBA
INSEAD
PhD
Université de Lausanne

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash CompensationSFr.396,010
Total Calculated CompensationSFr.751,032
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVN:VX SFr.92.35 CHF -1.20

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Alan George Lafley Chairman, Chief Executive Officer, President and Member of Proxy Committee
The Procter & Gamble Company
$6.4M
Ian C. Read Chairman, Chief Executive Officer and Chairman of Executive Committee
Pfizer Inc.
$1.8M
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Serge Weinberg Chairman, Interim Chief Executive Officer, Chairman of Appointments & Governance Committee and Chairman of Strategy Committee
Sanofi
€700.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.